Superior vena cava obstruction

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

SVC obstruction impedes venous return from the head, neck and upper limbs. Symptoms depend on speed, level and collateral formation: rapidly developing thrombotic obstruction can be dramatic, while slowly growing tumour may produce conspicuous collaterals before instability.

Management is determined by severity and cause. Airway or cerebral compromise favours urgent endovascular decompression and critical-care support; a stable patient needs contrast CT and a tissue strategy so that lymphoma, lung cancer and other tumours receive the correct definitive treatment.

Tumour and thrombus frequently coexist. The plan should explicitly state whether anticoagulation is indicated, whether an intravascular device can remain, whether stenting is needed for rapid relief and which specialty owns cancer treatment and follow-up.

Key points

SVC obstruction is usually caused by intrathoracic malignancy, but central venous catheters, pacemaker/ICD leads and other devices increasingly cause or contribute to central thrombosis.
Facial/neck and bilateral arm swelling, venous plethora and dilated chest-wall collaterals that worsen lying flat or bending forward are classic.
Stridor, confusion, reduced consciousness, syncope or haemodynamic compromise marks severe obstruction and requires immediate multidisciplinary escalation.
Contrast-enhanced venous-phase CT of the thorax is the investigation of choice; extend to abdomen/pelvis for cancer staging and add a pulmonary angiographic phase when PE is suspected.
In a stable patient with suspected malignancy, obtain tissue diagnosis with oncology/respiratory planning before definitive chemotherapy or radiotherapy whenever feasible.
Endovascular stenting can relieve severe malignant obstruction quickly and does not prevent later biopsy, chemotherapy or radiotherapy.
For catheter-associated thrombosis, therapeutic anticoagulation is generally required for at least 3 months; a needed, functioning catheter can often remain if symptoms improve.
Remove a device when it is no longer needed, non-functional or infected, anticoagulation is impossible, symptoms fail to improve, or thrombosis is limb- or life-threatening.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Intrathoracic malignancy

Lung cancer, lymphoma and metastatic mediastinal disease may compress or invade the superior vena cava. Tumour-associated hypercoagulability can add intraluminal thrombus, so both mechanisms may coexist.

Central venous device thrombosis

Peripherally inserted central catheters, tunnelled catheters, ports and pacemaker or defibrillator leads can cause endothelial injury and disturbed flow. Cancer, infection and previous thrombosis further increase device-associated clot risk.

Benign compression or central stenosis

Fibrosing mediastinitis, a large retrosternal goitre, thoracic aneurysmal disease or scarring after thoracic treatment can narrow the vessel externally. Previous instrumentation may also leave chronic central venous stenosis.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
The central venous lumen narrows
External compression, tumour invasion, fixed stenosis or thrombus reduce flow through the superior vena cava. Rapid thrombosis can create severe obstruction before alternative channels enlarge.
2
Upper-body venous pressure rises
Pressure backs up into the brachiocephalic, jugular and upper-limb veins, producing facial, neck and arm oedema, venous plethora and distended, often non-pulsatile neck veins.
3
Collateral channels develop
Blood is redirected through azygos, intercostal and chest-wall venous channels. Slowly developing disease permits better collateralisation, whereas sudden occlusion tends to produce more dramatic symptoms.
4
Critical organ effects emerge
Venous oedema can narrow the upper airway and raise intracranial venous pressure; severe obstruction may also reduce cardiac preload. Stridor, confusion, syncope or hypotension can therefore reflect dangerous physiology and require urgent assessment.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Upper-body venous congestion

Facial/periorbital and neck swelling, bilateral arm or breast swelling, cyanotic plethora, raised non-pulsatile neck veins and dilated chest-wall collaterals; often worse supine or on bending forward.

Respiratory symptoms

Dyspnoea, cough, hoarse voice, dysphagia and orthopnoea may reflect venous oedema, tumour compression, pleural effusion or coexisting airway disease.

Airway compromiseRed flag

Stridor, laryngeal oedema, inability to lie flat, severe work of breathing or rapidly increasing neck swelling requires immediate airway/critical-care and interventional discussion.

Cerebral or circulatory compromiseRed flag

Severe headache, visual disturbance, confusion, reduced consciousness, syncope, hypotension or renal hypoperfusion suggests critical venous obstruction.

Malignancy clues

Smoking history, weight loss, cough/haemoptysis, lymphadenopathy, known lung cancer, lymphoma, metastatic disease or a mediastinal mass.

Device-associated thrombosis clues

PICC, tunnelled line, port, dialysis catheter, pacemaker/ICD leads, recent line dysfunction, unilateral arm onset, arm/neck pain or previous thrombosis; infection and cancer can coexist.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Contrast-enhanced venous-phase CT thoraxFirst step
Why
Confirm the site/severity of obstruction and distinguish external compression, tumour invasion and intraluminal thrombus.
Interpretation and limitations
Defines collateral pathways and guides biopsy and stenting; extend to abdomen/pelvis for staging when indicated and add CTPA when pulmonary embolism is suspected.
02
FBC, U&E/eGFR, LFT, calcium and coagulation screen
Why
Assess cancer clues, organ function, contrast/anticoagulant safety and treatment readiness.
Interpretation and limitations
Thrombocytopenia, renal failure or hepatic dysfunction modifies biopsy and anticoagulation; normal blood tests do not exclude severe obstruction.
03
Tissue diagnosis
Why
Identify the malignancy before tumour-specific chemotherapy or radiotherapy.
Interpretation and limitations
With oncology/respiratory input, use the safest high-yield accessible node, bronchoscopy/EBUS, pleural sample or image-guided biopsy; do not delay lifesaving decompression for histology.
04
Upper-limb and neck venous duplex
Why
Demonstrate accessible axillary, subclavian or jugular thrombosis around a device.
Interpretation and limitations
A positive scan supports catheter-associated thrombosis, but a negative scan cannot exclude brachiocephalic or SVC disease; CT remains central.
05
Catheter and infection assessment
Why
Determine whether a device is needed, functional, malpositioned or infected.
Interpretation and limitations
Check tip position/function and take paired peripheral/line blood cultures if infection is suspected; infection or non-function favours removal with specialist planning.
06
Catheter venography during intervention
Why
Map central occlusion precisely and permit pressure assessment, thrombus treatment or stent deployment.
Interpretation and limitations
Used by interventional radiology when endovascular treatment is planned rather than as the routine first diagnostic test.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Heart failure

Heart failure can cause raised JVP and oedema, but pulmonary congestion, dependent leg swelling and a pulsatile venous waveform are more typical than facial plethora and chest-wall collaterals.

Angioedema or anaphylaxis

Rapid lip, tongue or facial swelling with urticaria, wheeze or systemic hypotension suggests an allergic process. Distended neck veins and established venous collaterals instead favour central obstruction.

Upper-limb deep-vein thrombosis

Isolated axillary or subclavian thrombosis usually causes unilateral arm pain and swelling. Bilateral upper-body congestion or a negative peripheral duplex does not exclude more central SVC disease.

Generalised fluid retention

Renal failure, nephrotic syndrome or severe hypoalbuminaemia produces more generalised or dependent oedema. Urine and blood findings, leg involvement and absence of chest collaterals help discriminate.

Airway or mediastinal compression

A mediastinal mass may cause cough, dysphagia or stridor without venous obstruction. Contrast CT can show whether airway or oesophageal compression, SVC narrowing and superimposed thrombus are isolated or coexist.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01criticalAirway, neurological or circulatory compromiseFirst stepStridor/laryngeal oedema, severe distress, confusion/reduced consciousness, syncope/hypotension or rapidly progressive obstruction.

1First: sit upright, monitor continuously, give oxygen if hypoxaemic and summon senior anaesthetic/critical-care support; avoid sedation and unnecessary upper-limb cannulation where feasible.
2Next: contact acute oncology/respiratory and interventional radiology immediately; obtain contrast CT only when the airway and circulation are sufficiently stable.
3Next: prioritise urgent endovascular stenting for rapid decompression when anatomically feasible; anticoagulate if acute thrombus is present and bleeding risk permits.
4EscalationEscalation: if stenting is unavailable or unsuitable, the responsible oncology team directs urgent tumour-sensitive treatment while critical care manages airway/cerebral complications.

02malignantStable suspected malignant obstructionClinical SVC obstruction without immediate airway, cerebral or circulatory compromise.

1First: discuss the same day with acute oncology/respiratory and obtain venous-phase contrast CT thorax, extending for staging as appropriate.
2Next: plan the safest rapid tissue diagnosis before chemotherapy or radiotherapy whenever feasible; involve haematology early if lymphoma is possible because corticosteroids can reduce biopsy yield.
3Next: for substantial symptoms, discuss stenting for prompt relief and consider dexamethasone 8 mg twice daily with the oncology team while diagnosis/treatment is organised.
4EscalationEscalation: use histology and staging to select chemotherapy, radiotherapy or combined treatment; escalate immediately if stridor, neurological change or haemodynamic compromise develops.

03device thrombosisCatheter- or lead-associated SVC thrombosisCT shows central thrombus related to a venous access device or cardiac lead.

1First: assess severity, PE, bleeding risk, platelet count/renal function, device need/function and infection; start therapeutic anticoagulation when safe.
2Next: retain a needed, functional and uninfected catheter if symptoms improve on anticoagulation; avoid automatic removal solely because thrombosis is present.
3Next: continue anticoagulation for at least 3 months, individualising longer treatment while the provoking device remains or active cancer persists.
4EscalationEscalation: remove with the relevant vascular access/cardiology team if unnecessary, non-functional or infected, anticoagulation is contraindicated, symptoms fail to resolve, or thrombosis threatens limb or life; discuss thrombus intervention/stenting for severe or refractory obstruction.

04follow-throughAfter decompression or initial therapySymptoms improve after stenting, anticoagulation or cancer-directed treatment.

1First: document facial/arm swelling, dyspnoea, neurological status, oxygen need and device function as the clinical baseline.
2DefinitiveNext: complete histology/staging and ensure a named oncology or thrombosis team owns definitive treatment and anticoagulation duration.
3Next: monitor stent/device patency and recurrent congestion; manage anticoagulant interactions, thrombocytopenia and procedures proactively.
4EscalationEscalation: recurrent swelling, new dyspnoea/PE features, bleeding, fever/line infection or neurological/airway symptoms needs urgent reassessment and repeat imaging.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Short-term reduction of tumour-associated oedema while imaging and definitive malignant SVCO treatment are organised; continue only if SVCO is confirmed and clinical benefit is evident.

Dexamethasone

8 mg orally twice daily, in the morning and at lunchtime; use IV administration at the same dose when swallowing is unsafe or impossible.

Discuss urgently with oncology/haematology, particularly before biopsy when lymphoma is possible because steroids can obscure histology. Monitor glucose, infection, mental state and GI risk; taper as symptoms improve and review stopping if no response after about 7 days.

Gastroprotection alongside the acute dexamethasone regimen used in NHS oncology guidance.

Omeprazole

20 mg orally once daily while high-dose dexamethasone is used when gastroprotection is indicated.

Review need when steroids stop; consider interactions and alternative lansoprazole 30 mg once daily where appropriate.

One therapeutic anticoagulant option for thrombotic SVC obstruction, including cancer- or device-associated thrombosis, when immediate anticoagulation is safe.

Enoxaparin

1 mg/kg by subcutaneous injection every 12 hours for acute therapeutic anticoagulation; if creatinine clearance is 15–30 mL/min, the SmPC treatment dose is 1 mg/kg once daily.

Use actual weight; enoxaparin is not recommended when creatinine clearance is below 15 mL/min outside prevention of thrombus in the extracorporeal dialysis circuit. Check platelets, bleeding, recent procedures and previous HIT. Cancer type, thrombocytopenia, drug interactions and planned biopsy/stenting may favour a different LMWH or DOAC strategy after specialist review.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Upper-airway compromise

Progressive pharyngeal or laryngeal venous oedema can produce hoarseness, stridor and inability to lie flat. Rapid deterioration may make imaging or airway intervention hazardous without critical-care planning.

Cerebral venous congestion

Raised intracranial venous pressure can cause severe headache, visual disturbance, confusion, reduced consciousness or seizures. These features indicate critical obstruction requiring immediate multidisciplinary escalation.

Haemodynamic compromise

Severe obstruction can limit venous return to the right atrium, reducing cardiac preload and output. Hypotension, syncope or renal hypoperfusion signal circulatory involvement but should also prompt assessment for pulmonary embolism, tamponade, sepsis and other coexisting shock mechanisms.

Thrombus propagation and embolism

Device-related or tumour-associated thrombus may extend into brachiocephalic and upper-limb veins, threaten vascular access or embolise to the lungs, complicating anticoagulation and intervention planning.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Serially record respiratory rate/work, oxygen saturation, ability to lie flat, voice/stridor and neurological state during the acute phase.
Measure facial/neck and arm swelling, collateral prominence, headache and functional dyspnoea to document response.
During anticoagulation, monitor bleeding, FBC/platelets, renal/hepatic function and interactions; reassess around biopsy, chemotherapy and thrombocytopenia.
Check venous access function and infection signs; arrange repeat imaging for non-response or recurrent symptoms rather than routinely removing a functioning line.
After stenting, follow the interventional plan for patency, antithrombotic treatment and access-site complications, and urgently investigate recurrent congestion.
Ensure histology, staging and definitive cancer treatment continue after symptom relief; a successful stent is not the end of the diagnostic pathway.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Severity outranks aetiology initially

Airway, cerebral or haemodynamic compromise dictates urgent decompression even before the tumour type or complete thrombotic mechanism is known.

CT must answer two questions

Look for both the compressing/invasive mass and superimposed thrombus; treating only one mechanism can leave symptoms unresolved.

Stenting preserves options

Rapid endovascular relief can be followed by biopsy, chemotherapy or radiotherapy and is especially useful when symptoms are severe or the cancer response will not be immediate.

Do not reflexively pull the line

A required, functioning, uninfected catheter may remain during anticoagulation; removal can jeopardise access and does not itself treat central thrombus.

Steroids are not definitive treatment

They may reduce oedema in selected malignant obstruction but can alter lymphoma histology and should never delay CT, tissue planning or stent discussion.

Upper-limb duplex has a blind spot

It can identify accessible jugular/axillary/subclavian thrombosis but cannot reliably exclude brachiocephalic or SVC obstruction.

11Common pitfallsFrequent interpretation and management errors.

01
Sending a patient with stridor or confusion for unmonitored imaging before airway/critical-care escalation.
02
Ordering only a chest radiograph or upper-limb ultrasound and treating a negative result as exclusion of SVC disease.
03
Starting tumour-specific radiotherapy without tissue planning in a stable undiagnosed patient when biopsy is feasible.
04
Giving corticosteroids reflexively before discussing possible lymphoma histology with haematology/oncology.
05
Automatically removing a needed, functioning, uninfected catheter instead of anticoagulating and applying guideline removal criteria.